Minh T. Truong
Experienced in RASopathies

Dr. Minh T. Truong

Radiation Oncology
Boston University Radiation Oncology Inc
830 Harrison Ave, Ll100, 
Boston, MA 
Experienced in RASopathies
Boston University Radiation Oncology Inc
830 Harrison Ave, Ll100, 
Boston, MA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Minh Truong is a Radiation Oncologist in Boston, Massachusetts. Dr. Truong is rated as an Experienced provider by MediFind in the treatment of RASopathies. Her top areas of expertise are Laryngeal Cancer, Throat Cancer, Tongue Cancer, Pituitary Tumor, and Glossectomy.

Her clinical research consists of co-authoring 82 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Radiation Oncology
Licenses
Radiology in MA
Hospital Affiliations
Boston Medical Center
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

BMC HealthNet
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Tufts
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D

Locations

BOSTON UNIVERSITY RADIATION ONCOLOGY INC
830 Harrison Ave, Ll100, Boston, MA 02118

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

A Randomized Phase II Trial for Patients With p16 Positive, Non-Smoking Associated, Locoregionally Advanced Oropharyngeal Cancer
A Randomized Phase II Trial for Patients With p16 Positive, Non-Smoking Associated, Locoregionally Advanced Oropharyngeal Cancer
Enrollment Status: Completed
Publish Date: October 09, 2025
Intervention Type: Drug, Radiation
Study Drug: Cisplatin
Study Phase: Phase 2
A Randomized Phase II/III Trial of De-Intensified Radiation Therapy for Patients With Early-Stage, P16-Positive, Non-Smoking Associated Oropharyngeal Cancer
A Randomized Phase II/III Trial of De-Intensified Radiation Therapy for Patients With Early-Stage, P16-Positive, Non-Smoking Associated Oropharyngeal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: October 09, 2025
Intervention Type: Other, Procedure, Drug, Biological, Radiation
Study Drugs: Cisplatin, Nivolumab
Study Phase: Phase 2/Phase 3
A Phase II-R and a Phase III Trial Evaluating Both Erlotinib (Ph II-R) and Chemoradiation (Ph III) as Adjuvant Treatment for Patients With Resected Head of Pancreas Adenocarcinoma
A Phase II-R and a Phase III Trial Evaluating Both Erlotinib (Ph II-R) and Chemoradiation (Ph III) as Adjuvant Treatment for Patients With Resected Head of Pancreas Adenocarcinoma
Enrollment Status: Completed
Publish Date: October 08, 2025
Intervention Type: Other, Procedure, Drug, Radiation
Study Drugs: Capecitabine, Chemotherapy, Erlotinib hydrochloride, Fluorouracil, Gemcitabine hydrochloride
Study Phase: Phase 3
Randomized Phase II/III Trial of Radiotherapy With Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy With Concurrent Cetuximab in Patients With Locoregionally Advanced Head and Neck Cancer With a Contraindication to Cisplatin
Randomized Phase II/III Trial of Radiotherapy With Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy With Concurrent Cetuximab in Patients With Locoregionally Advanced Head and Neck Cancer With a Contraindication to Cisplatin
Enrollment Status: Completed
Publish Date: September 23, 2025
Intervention Type: Other, Biological, Radiation
Study Drugs: Cetuximab, Durvalumab
Study Phase: Phase 2/Phase 3
A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally-Advanced Resected Head and Neck Cancer
A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally-Advanced Resected Head and Neck Cancer
Enrollment Status: Active_not_recruiting
Publish Date: July 20, 2025
Intervention Type: Biological, Radiation
Study Drug: Cetuximab
Study Phase: Phase 3
A Randomized Phase II/Phase III Study of Adjuvant Concurrent Radiation and Chemotherapy Versus Radiation Alone in Resected High-Risk Malignant Salivary Gland Tumors
A Randomized Phase II/Phase III Study of Adjuvant Concurrent Radiation and Chemotherapy Versus Radiation Alone in Resected High-Risk Malignant Salivary Gland Tumors
Enrollment Status: Active_not_recruiting
Publish Date: February 13, 2025
Intervention Type: Drug, Radiation
Study Drug: Cisplatin
Study Phase: Phase 2
Randomized Phase II and Phase III Studies of Individualized Treatment for Nasopharyngeal Carcinoma Based on Biomarker Epstein Barr Virus (EBV) Deoxyribonucleic Acid (DNA)
Randomized Phase II and Phase III Studies of Individualized Treatment for Nasopharyngeal Carcinoma Based on Biomarker Epstein Barr Virus (EBV) Deoxyribonucleic Acid (DNA)
Enrollment Status: Active_not_recruiting
Publish Date: November 06, 2024
Intervention Type: Other, Drug, Radiation
Study Drugs: Cisplatin, Fluorouracil, Gemcitabine Hydrochloride, Paclitaxel
Study Phase: Phase 2/Phase 3
View 6 Less Clinical Trials

82 Total Publications

The climate and health impact of U.S. radiation therapy: estimating greenhouse gas emissions, DALYs, and potential of hypofractionation.
The climate and health impact of U.S. radiation therapy: estimating greenhouse gas emissions, DALYs, and potential of hypofractionation.
Journal: Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
Published: May 22, 2025
Similar Doctors
Experienced in RASopathies
Dr. Helen A. Shih
Radiation Oncology
Experienced in RASopathies
Dr. Helen A. Shih
Radiation Oncology

Massachusetts General Physicians Organization Inc

55 Fruit St, 
Boston, MA 
 (2.0 miles away)
617-724-0287
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Helen Shih is a Radiation Oncologist in Boston, Massachusetts. Dr. Shih is rated as a Distinguished provider by MediFind in the treatment of RASopathies. Her top areas of expertise are Meningioma, Brain Tumor, Astrocytoma, Acoustic Neuroma, and Tissue Biopsy. Dr. Shih is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Truong's expertise for a condition
ConditionClose
    View All 13 Advanced Conditions
    View All 52 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile